Skip Navigation


Annals of Oncology Advance Access originally published online on November 20, 2007
Annals of Oncology 2008 19(3):481-486; doi:10.1093/annonc/mdm486
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
19/3/481    most recent
mdm486v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ng, R.
Right arrow Articles by Chen, E. X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ng, R.
Right arrow Articles by Chen, E. X.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

breast cancer

Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006

R. Ng1, G. R. Pond2, P. A. Tang1, P. W. MacIntosh1, L. L. Siu1 and E. X. Chen1,*

1 Department of Medical Oncology and Hematology, Princess Margaret Hospital, Faculty of Medicine, University of Toronto, Toronto
2 Biostatistics, Princess Margaret Hospital, Toronto, Canada

* Correspondence to: Dr E. Chen, Department of Medical Oncology and Hematology, Princess Margaret Hospital, Suite 5-719, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9. Tel: +1 416-946-2263; Fax: +1 416-946-4467; E-mail: eric.chen{at}uhn.on.ca

Background: Although disease-free survival (DFS) is accepted as a valid end point in adjuvant breast cancer trials, improvement in 2-year DFS has never been formally established as an adequate correlate for 5-year overall survival (OS). We set out to ascertain if changes in 2-year DFS can be used to accurately predict 5-year OS changes.

Design: We conducted a systematic Medline search (1966–2006) for randomized adjuvant breast cancer trials of >100 patients per arm with 2-year DFS and 5-year OS data. A univariate regression model weighted by trial sample size was constructed to determine whether 2-year DFS differences between treatment arms within trials were predictive of 5-year OS differences.

Results: A total of 126 studies containing 149 treatment comparisons met the inclusion criteria. Difference in 2-year DFS was a significant predictor of difference in 5-year OS. For every 1% increase in 2-year DFS difference, the 5-year OS difference increased by 0.5%–0.55%. The proportion of variation explained ranged from 0.38 to 0.42, with a wide prediction interval.

Conclusion: There is a statistically significant correlation, of moderate strength, between difference in 2-year DFS between treatment comparisons and difference in 5-year OS but the correlation is not strong enough to be used as a predictor.

Key words: breast cancer, correlation, disease-free survival, overall survival

Received for publication July 18, 2007. Revision received September 13, 2007. Accepted for publication September 17, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.